Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | PPARG | P37231 | 5/20 | 0.36 |
| ▸ | PPARA | Q07869 | 5/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6036278 | 1.00 | KMT2A (0.43) | KMT2APPARGPPARACYP1A2CYP2C9 | |
| SCHEMBL6036686 | 0.83 | PPARA (0.40) | PPARGPPARATDP1PPARDKDM4E | |
| SCHEMBL6036690 | 0.83 | PPARA (0.40) | PPARGPPARATDP1PPARDKDM4E | |
| SCHEMBL29170202 | 0.82 | PPARG (0.48) | KMT2APPARGPPARACYP1A2ACHE | |
| SCHEMBL7903853 | 0.82 | PPARG (0.48) | KMT2APPARGPPARACYP1A2ACHE | |
| SCHEMBL7902134 | 0.81 | PPARG (0.34) | KMT2APPARGPPARAELANETDP1 | |
| SCHEMBL7903878 | 0.80 | PPARG (0.34) | PPARGPPARACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL7894784 | 0.80 | PPARG (0.34) | PPARGPPARAELANETDP1NFKB1 | |
| SCHEMBL13570965 | 0.77 | CYP1A2 (0.50) | KMT2APPARGPPARACYP1A2CYP2C9 | |
| SCHEMBL13570964 | 0.77 | CYP1A2 (0.50) | KMT2APPARGPPARACYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644025-A4 | WATER-SOLUBLE SHPS AS NOVEL ALKYLATING AGENTS | VION PHARMACEUTICALS INC (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1644025-A1 | WATER-SOLUBLE SHPS AS NOVEL ALKYLATING AGENTS | Vion Pharmaceuticals, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050043244-A1 | Water-soluble SHPs as novel alkylating agents | VION PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | US | disclosed |
| US-6855695-B2 | Water-soluble SHPs as novel alkylating agents | VION PHARMACEUTICALS, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| WO-2005004897-A1 | WATER-SOLUBLE SHPS AS NOVEL ALKYLATING AGENTS | VION PHARMACEUTICALS, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| US-20040254103-A1 | WATER-SOLUBLE SHPS AS NOVEL ALKYLATING AGENTS | NANOSHIFT, LLC | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254103-A1 | WATER-SOLUBLE SHPS AS NOVEL ALKYLATING AGENTS | SHPRH, OGFR, COG3 | KMT2A 1653/4885PPARG 3545/4885PPARA 4021/4885 |
| US-20050043244-A1 | Water-soluble SHPs as novel alkylating agents | GRM3, GRIA3, SHPRH | KMT2A 2306/4885PPARG 2900/4885PPARA 3768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.